PPIase-Parvulin Inhibitor
(Synonyms: 1,3,6,8-四氢-1,3,6,8-四氧代-苯并[LMN][3,8]菲咯啉-2,7-二乙酸2,7-二乙酯,HIC 016C,PiB) 目录号 : GC12953
A cell-permeable Pin1 and Pin4 inhibitor
Cas No.:64005-90-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Targets: Pin1 and Pin4
IC50: 1.5 and 1.0 μM for Pin1 and Pin4, respectively.
PPIase-Parvulin Inhibitor is a cell-permeable inhibitor of the PPIases Pin1 and Pin4, with the IC50 values of 1.5 and 1.0 μM, respectively [1].
In Vitro: PPIase-Parvulin Inhibitor could significantly inhibit a number of cancer cell lines such as HSC2, HSC4, HCT116, SKOV3 that overexpressed Pin1 and Pin4, with the IC50 values ranging from 2-5 μM, while cancer cell lines with a low expression of Pin1 such as HLE and HepG2 were less sensitive to PPIase-Parvulin Inhibitor [1]. Besides, 0.5 μg/ml PPIase-Parvulin Inhibitor could reduce MCF10A-Myc cells colony formation which was induced by Pin1 overexpression [2]. Furthermore, in NOP6 mouse mammary tumor cells, 1.5 μM PPIase-Parvulin Inhibitor could significantly impair mammosphere formation efficiency (MFE) at the M2 level [3].
In Vivo: No data available recently.
Clinical trial: No data available recently.
References:
[1] Uchida T, Takamiya M, Takahashi M, et al. Pin1 and Par14 Peptidyl Prolyl Isomerase Inhibitors Block Cell Proliferation[J]. Chemistry & Biology, 2003, 10(1):15.
[2] Farrell A S, Pelz C, Wang X, et al. Pin1 Regulates the Dynamics of c-Myc DNA Binding To Facilitate Target Gene Regulation and Oncogenesis[J]. Molecular and Cellular Biology, 2013, 33(15): 2930-2949.
[3] Rustighi A, Zannini A, Tiberi L, et al. Prolyl‐isomerase Pin1 controls normal and cancer stem cells of the breast[J]. Embo Molecular Medicine, 2014, 6(1): 99-119.
| Cas No. | 64005-90-9 | SDF | |
| 别名 | 1,3,6,8-四氢-1,3,6,8-四氧代-苯并[LMN][3,8]菲咯啉-2,7-二乙酸2,7-二乙酯,HIC 016C,PiB | ||
| 化学名 | 1,3,6,8-tetrahydro-1,3,6,8-tetraoxo-benzo[lmn][3,8]phenanthroline-2,7-diacetic acid, 2,7-diethyl ester | ||
| Canonical SMILES | O=C1N(CC(OCC)=O)C(C2=CC=C(C3=C4C=CC1=C23)C(N(CC(OCC)=O)C4=O)=O)=O | ||
| 分子式 | C22H18N2O8 | 分子量 | 438.4 |
| 溶解度 | ≤10mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.281 mL | 11.4051 mL | 22.8102 mL |
| 5 mM | 0.4562 mL | 2.281 mL | 4.562 mL |
| 10 mM | 0.2281 mL | 1.1405 mL | 2.281 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。